NCT00551356View on ClinicalTrials.gov

Lispro Mix 25 vs. Glargine in Type 2 Diabetics

PHASE3CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

July 31, 2003

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

Insulin lispro mix 25

Insulin lispro mix 25 given SC twice-daily in conjunction with oral antidiabetic medications.

DRUG

Glargine

Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.

Trial Locations (1)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00551356 - Lispro Mix 25 vs. Glargine in Type 2 Diabetics | Biotech Hunter | Biotech Hunter